Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8489742 | 0.83 | P2RX7 (0.36) | P2RX7ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL8006029 | 0.81 | P2RX7 (0.37) | P2RX7CYP11B1CYP11B2 | |
| SCHEMBL10378077 | 0.81 | P2RX7 (0.37) | P2RX7CYP11B1CYP11B2POLB | |
| SCHEMBL4884756 | 0.78 | CYP11B1 (0.35) | ALDH1A1KDM4EMAPTLMNACYP11B1 | |
| SCHEMBL7803953 | 0.77 | KDM4E (0.34) | P2RX7ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL9408078 | 0.76 | ALDH1A1 (0.36) | P2RX7ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL9164742 | 0.76 | ALDH1A1 (0.38) | ALDH1A1LMNA | |
| SCHEMBL7803973 | 0.76 | P2RX7 (0.32) | P2RX7 | |
| SCHEMBL3500675 | 0.75 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL5326782 | 0.74 | BRD4 (0.32) | P2RX7ALDH1A1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024240240-A1 | IMIDAZOLE DERIVATIVES, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4097092-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | Protego Biopharma, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115298168-A | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 普罗泰格生物制药公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021154842-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-2909197-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-03-04 | — | — | EP | disclosed |
| US-9663512-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2017-05-30 | — | — | US | disclosed |
| US-20150266873-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-0451538-B1 | Use of pyridoindole derivatives in the treatment of ischemic disorders | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0361317-B1 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-04-05 | — | — | EP | disclosed |
| US-5290785-A | Therapeutic agent for ischemic diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0269599-B1 | Substituted 1H-imidazoles | UCB SA (BE) | 1993-12-15 | — | — | EP | disclosed |
| US-5173493-A | For treatment or prevention of nausea or vomiting | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-12-22 | — | — | US | disclosed |
| US-5141945-A | 5-Hydroxytryptamine antagonists, treatment or prevention of nausea and vomiting | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0451538-A2 | Use of pyridoindole derivatives in the treatment of ischemic disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-16 | — | — | EP | disclosed |
| EP-0361317-A2 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |
| EP-0269599-A2 | Substituted 1H-imidazoles | U C B, S.A. (BE) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | P2RX7 4652/4885ALDH1A1 3122/4885KDM4E 4751/4885 |
| US-20150266873-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PC, BAD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P2RX7 1121/4885ALDH1A1 733/4885KDM4E 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.